Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones

Martin Pette, Paolo A. Muraro, Dagmar F. Pette, H. Dinter, Henry F. McFarland, Roland Martin

Research output: Contribution to journalArticle

Abstract

Proinflammatory cytokines, secreted by autoreactive CD4+ T lymphocytes may contribute to the pathogenesis of several human autoimmune diseases, including multiple sclerosis (MS). Since the antigen specificities of these T cells are not known at present, therapeutic strategies aiming at common effector pathways, in particular cytokine secretion, may be more feasible in the near future. We have studied the influence of the isoenzyme-specific phosphodiesterase inhibitor rolipram on the proliferation and cytokine secretion of human myelin basic protein-specific T cell clones. The inhibition of proliferation correlated with interference with the IL-2/IL-2 receptor system, while the effects of rolipram on several T helper 1-(TNF-α, TNF-β, IFN-γ) and T helper 2-like cytokines (IL-4, IL-13) as well as IL-10 revealed an interesting drug profile, with preferential inhibition of TNF-β, TNF-α and IL-10. This profile suggest that rolipram differs from other currently used immunomodulatory drugs. Copyright (C) 1999 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)147-156
Number of pages10
JournalJournal of Neuroimmunology
Volume98
Issue number2
DOIs
StatePublished - Aug 3 1999
Externally publishedYes

Fingerprint

Type 4 Cyclic Nucleotide Phosphodiesterase
Rolipram
Myelin Sheath
Clone Cells
Cytokines
T-Lymphocytes
Interleukin-10
T-Cell Antigen Receptor Specificity
Phosphodiesterase Inhibitors
Interleukin-13
Interleukin-2 Receptors
Interleukin-4
Pharmaceutical Preparations
Isoenzymes
Autoimmune Diseases
Multiple Sclerosis
Interleukin-2
Antigens

Keywords

  • Multiple sclerosis
  • Phosphodiesterase inhibition
  • Rolipram
  • T lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones. / Pette, Martin; Muraro, Paolo A.; Pette, Dagmar F.; Dinter, H.; McFarland, Henry F.; Martin, Roland.

In: Journal of Neuroimmunology, Vol. 98, No. 2, 03.08.1999, p. 147-156.

Research output: Contribution to journalArticle

Pette, Martin ; Muraro, Paolo A. ; Pette, Dagmar F. ; Dinter, H. ; McFarland, Henry F. ; Martin, Roland. / Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones. In: Journal of Neuroimmunology. 1999 ; Vol. 98, No. 2. pp. 147-156.
@article{8066240893bb43d3bd2948cb536eb5c8,
title = "Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones",
abstract = "Proinflammatory cytokines, secreted by autoreactive CD4+ T lymphocytes may contribute to the pathogenesis of several human autoimmune diseases, including multiple sclerosis (MS). Since the antigen specificities of these T cells are not known at present, therapeutic strategies aiming at common effector pathways, in particular cytokine secretion, may be more feasible in the near future. We have studied the influence of the isoenzyme-specific phosphodiesterase inhibitor rolipram on the proliferation and cytokine secretion of human myelin basic protein-specific T cell clones. The inhibition of proliferation correlated with interference with the IL-2/IL-2 receptor system, while the effects of rolipram on several T helper 1-(TNF-α, TNF-β, IFN-γ) and T helper 2-like cytokines (IL-4, IL-13) as well as IL-10 revealed an interesting drug profile, with preferential inhibition of TNF-β, TNF-α and IL-10. This profile suggest that rolipram differs from other currently used immunomodulatory drugs. Copyright (C) 1999 Elsevier Science B.V.",
keywords = "Multiple sclerosis, Phosphodiesterase inhibition, Rolipram, T lymphocytes",
author = "Martin Pette and Muraro, {Paolo A.} and Pette, {Dagmar F.} and H. Dinter and McFarland, {Henry F.} and Roland Martin",
year = "1999",
month = "8",
day = "3",
doi = "10.1016/S0165-5728(99)00088-0",
language = "English (US)",
volume = "98",
pages = "147--156",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones

AU - Pette, Martin

AU - Muraro, Paolo A.

AU - Pette, Dagmar F.

AU - Dinter, H.

AU - McFarland, Henry F.

AU - Martin, Roland

PY - 1999/8/3

Y1 - 1999/8/3

N2 - Proinflammatory cytokines, secreted by autoreactive CD4+ T lymphocytes may contribute to the pathogenesis of several human autoimmune diseases, including multiple sclerosis (MS). Since the antigen specificities of these T cells are not known at present, therapeutic strategies aiming at common effector pathways, in particular cytokine secretion, may be more feasible in the near future. We have studied the influence of the isoenzyme-specific phosphodiesterase inhibitor rolipram on the proliferation and cytokine secretion of human myelin basic protein-specific T cell clones. The inhibition of proliferation correlated with interference with the IL-2/IL-2 receptor system, while the effects of rolipram on several T helper 1-(TNF-α, TNF-β, IFN-γ) and T helper 2-like cytokines (IL-4, IL-13) as well as IL-10 revealed an interesting drug profile, with preferential inhibition of TNF-β, TNF-α and IL-10. This profile suggest that rolipram differs from other currently used immunomodulatory drugs. Copyright (C) 1999 Elsevier Science B.V.

AB - Proinflammatory cytokines, secreted by autoreactive CD4+ T lymphocytes may contribute to the pathogenesis of several human autoimmune diseases, including multiple sclerosis (MS). Since the antigen specificities of these T cells are not known at present, therapeutic strategies aiming at common effector pathways, in particular cytokine secretion, may be more feasible in the near future. We have studied the influence of the isoenzyme-specific phosphodiesterase inhibitor rolipram on the proliferation and cytokine secretion of human myelin basic protein-specific T cell clones. The inhibition of proliferation correlated with interference with the IL-2/IL-2 receptor system, while the effects of rolipram on several T helper 1-(TNF-α, TNF-β, IFN-γ) and T helper 2-like cytokines (IL-4, IL-13) as well as IL-10 revealed an interesting drug profile, with preferential inhibition of TNF-β, TNF-α and IL-10. This profile suggest that rolipram differs from other currently used immunomodulatory drugs. Copyright (C) 1999 Elsevier Science B.V.

KW - Multiple sclerosis

KW - Phosphodiesterase inhibition

KW - Rolipram

KW - T lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=0032981341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032981341&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(99)00088-0

DO - 10.1016/S0165-5728(99)00088-0

M3 - Article

C2 - 10430048

AN - SCOPUS:0032981341

VL - 98

SP - 147

EP - 156

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 2

ER -